The case for & against
Bull & Bear analysis
Bullish
Koru Medical Systems (NASDAQ: KORU) is a healthcare company specializing in the development and commercialization of innovative infusion systems, particularly focusing on subcutaneous immunoglobulin (SCIG) therapies. The company leverages a recurring revenue model, catering to a growing patient base by offering advanced drug delivery solutions for chronic conditions. Positioned strategically within the evolving healthcare landscape, Koru aims to capture significant growth opportunities as demand shifts towards at-home treatment solutions alongside expanding its product portfolio in oncology and international markets.
Bull says
- ↑Q1 2026 revenue $11.8M (+22% YoY); full-year guide $47.5–50M
- ↑International sales +35% YoY from pre-fill SCIG conversions
- ↑Five drug submissions planned for 2025; oncology market target $40M→$120M
- ↑Recurring base of ~60,000 patients; 61.5% gross margin (target 61–63%)
- ↑Forecast positive adjusted EBITDA in back half of 2026
- ↑Differentiated by SCIG innovation and pre-fill device leadership
Bear says
- ↓Negative earnings yield highlights ongoing profitability drag
- ↓Analyst revisions weak, suggesting growth expectations may falter
- ↓Regulatory timelines could delay key product approvals and sales
- ↓Supply-chain vulnerabilities risk production and delivery disruptions
- ↓Intense oncology device competition may dilute market share
- ↓High stock volatility and low institutional ownership pressure sentiment
Earnings Call · Q4 2026 · Mgmt. Guidance
Updated 05-12-2026bullish
Transcript signals
Bull points
- We're really excited about that. The other one's a molecule in early phase one. It's a multi-indication drug. In total, this represents approximately 3 million annual infusions between the two of them. So really excited to add those into our pipeline and get the work going on the feasibility side to keep these moving through the pharmaceutical pipeline and into our future prospects.
- this is our first collaboration with UCB and it diversifies our revenue beyond just SCIG in a meaningful way.
- So we're pretty well positioned to continue to grow in that market. You know, at the time, we're seeing pre-filled syringes there as being important, just as we kind of see in these other international markets. So as those pre-fills continue to grow, we expect that we're going to be growing with them.
Read full transcript analysis ›